Loading clinical trials...
Loading clinical trials...
A Two-arm, Phase 1b/2 Study of Duvelisib Administered in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)
Conditions
Interventions
Duvelisib
Rituximab
+1 more
Locations
21
United States
Los Angeles, California, United States
Palo Alto, California, United States
Hackensack, New Jersey, United States
Rochester, New York, United States
Dallas, Texas, United States
Kortrijk, Belgium
Start Date
December 1, 2014
Primary Completion Date
January 17, 2017
Completion Date
May 1, 2017
Last Updated
September 28, 2023
Lead Sponsor
SecuraBio
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions